Prostate Cancer

An analysis of racial disparities in prostate cancer treatment found that treatment underuse is rare, but when it does occur, it is almost exclusively in black men.

Associated Medical Professionals of New York, a urology and radiation oncology practice, seeks to give its physician partners an equal share of its financial success while rewarding all staff members according to their levels of responsibility and workflow intensity.

Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses the role of chemotherapy versus abiraterone (Zytiga) for patients with metastatic castration-resistant prostate cancer (mCRPC).

In results from the North Carolina Prostate Cancer Comparative Effectiveness and Survivorship Study, 52.6% said that preserving sexual function was “very important,” but only 43.4% were assigned to active surveillance.

Julie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses sipuleucel-T (Provenge) in patients with metastatic castration-resistant prostate cancer.

In a study of neoadjuvant sonidegib in men with high-risk localized prostate cancer undergoing prostatectomy, hedgehog pathway activity was detectable at baseline.

Prostate cancer has recently been recognized as a genomically heterogeneous disease with subtypes similar to breast or ovarian cancers.

The phase III ERA223 trial exploring radium-223 dichloride plus abiraterone acetate in patients with asymptomatic or mildly symptomatic chemotherapy-naïve metastatic castration-resistant prostate cancer has been unblinded early.

Both magnetic resonance imaging and prostate cancer antigen 3 tests can predict a positive prostate biopsy and are helpful in identifying high-risk prostate cancer.

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the ARCHES study for patients with prostate cancer.

A second course of radium-223 was associated with minimal hematologic toxicity and low radiographic bone progression rates in a phase I/II study of men with metastatic castration-resistant prostate cancer.

Tanya B. Dorff, MD, discusses several important components regarding metastatic castration-resistant prostate cancer treatment, including the addition of novel drugs, optimal therapeutic sequences, and the identification of predictive biomarkers.

William R. Berry, MD, medical oncologist, Duke University, discusses novel imaging techniques for patients with prostate cancer.

The European Commission has approved abiraterone acetate (Zytiga) in combination with prednisone/prednisolone for the treatment of adult men with newly-diagnosed high-risk metastatic hormone-sensitive prostate cancer.

Jonathan Warner, MD, discusses the evolving role of surgery and radiation therapy in the treatment landscape for patients with prostate cancer.

Malcom Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, discusses the significance of the PROTECT study in prostate cancer during the 2017 EMUC Congress.

Log LDH was the strongest predictor for overall survival with radium-223 for men with metastatic castration resistant prostate cancer.

Use of the novel prostate imaging reporting and data system enhanced the ability to determine prostate cancer stage versus standard multiparametric MRI alone, offering advantages for deciding the extent of resection needed during an endoscopic radical prostatectomy.

Rucaparib, a drug approved for the treatment of ovarian cancer, might also be used to treat patients with metastatic castration-resistant prostate cancer.

Jonathan N. Warner, MD, reconstructive urologist, City of Hope, discusses the future of surgery for patients with prostate cancer.

Tanya B. Dorff, MD, associate professor of clinical medicine, University of Southern California, discusses current agents available for patients with metastatic castration-resistant prostate cancer (mCRPC).

William Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai School of Medicine, discusses the management of patients with hormone-sensitive prostate cancer.

Przemyslaw W. Twardowski, MD, discusses a variety of factors to consider when treating patients with prostate cancer.

Guru P. Sonpavde, MD, discusses degarelix, androgen-deprivation therapy, and ongoing trials with immunotherapy that are crucial to advancing the treatment of patients with prostate cancer.

Sumanta K. Pal, MD, discusses advancements in prostate cancer, bladder cancer, and promising results in kidney cancer.